ストックスクリーナーアプリを入手
2.8754
0.20%
0.0054
Black Diamond Therapeutics Inc (BDTX) 最新ニュース
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Black Diamond Sued Over Patented Cancer Drug Discovery Methods - Bloomberg Law News
Black Diamond stock: Weighing catalysts vs. concentration - MSN
Trading Action: Will Black Diamond Therapeutics Inc benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - baoquankhu1.vn
Volatility Watch: Will Black Diamond Therapeutics Inc benefit from AI trends2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts - National Today
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Market Fear: Does Black Diamond Therapeutics Inc outperform in volatile marketsGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Investment Recap: How does Black Diamond Therapeutics Inc score in quality rankingsWeekly Investment Summary & Long-Term Safe Return Strategies - baoquankhu1.vn
Risk Recap: Is Black Diamond Therapeutics Inc part of any ETFDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
BDTX: Insights from Silevertinib Data on EGFR NSCLC Growth Potential - Bitget
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026 - TradingView
Black Diamond Stock: Weighing Catalysts vs. Concentration - Yahoo Finance
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside - TradingView
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 2%Should You Buy? - MarketBeat
Aug Patterns: Should I average down on Ainos Inc stock2026 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
Buy Signal: How does Black Diamond Therapeutics Inc score in quality rankingsWeekly Stock Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BDTX Should I Buy - Intellectia AI
BDTX Stock Price, Quote & Chart | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Retail Surge: Does Black Diamond Therapeutics Inc align with a passive investing strategy2026 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Published on: 2026-03-30 21:41:19 - baoquankhu1.vn
Sentiment Review: Can Black Diamond Therapeutics Inc maintain sales growthTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Gain Therapeutics (GANX), CG Oncology, Inc. (CGON) - The Globe and Mail
Invesco Dynamic Credit Opportunity Fund's Black Diamond Therapeutics Inc(BDTX) Holding History - gurufocus.com
Market Review: Is Black Diamond Therapeutics Inc a strong growth stock2026 Biggest Moves & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Will Black Diamond Therapeutics Inc benefit from rate cuts2026 Drop Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program - Yahoo Finance
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity - Seeking Alpha
Top 5 Stocks Under $5 That Could Triple - Insider Monkey
Technical Analysis: Will Black Diamond Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Volume Summary: Can Black Diamond Therapeutics Inc maintain sales growthDollar Strength & Low Risk High Reward Ideas - baoquankhu1.vn
Exit Recap: Is Black Diamond Therapeutics Inc stock good for income investorsMarket Movement Recap & AI Optimized Trade Strategies - baoquankhu1.vn
Black Diamond (BDTX) director receives 6,919-share stock grant - Stock Titan
Black Diamond Therapeutics (BDTX) director receives 6,105-share stock grant in lieu of cash - Stock Titan
VIX Spike: Is Black Diamond Therapeutics Inc part of any ETFEarnings Trend Report & Low Risk High Reward Ideas - baoquankhu1.vn
EV Market: Is Black Diamond Therapeutics Inc benefiting from interest rate changesQuarterly Profit Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Stock Ratings | Baird Bank raises CRCL's price target to $138; Rodman & Renshaw initiates coverage of BTAI with a "buy" recommendation and a $17 price target, representing a potential upside of 882.66%. - Sahm
Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX) - The Globe and Mail
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives - simplywall.st
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen - The Globe and Mail
Investment Recap: Does Black Diamond Therapeutics Inc align with a passive investing strategy2026 Setups & Weekly High Potential Alerts - baoquankhu1.vn
BDTX: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) Stock - MarketBeat
Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating - marketscreener.com
Black Diamond: Fourth Quarter Financial Results Overview - Bitget
Black Diamond Therapeutics 2025 Annual Report – Clinical-Stage Oncology Pipeline, MasterKey Therapies, and Regulatory Overview - Minichart
Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials i - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Issues Quarterly Earnings Results - MarketBeat
Black Diamond: Q4 Earnings Snapshot - 10TV
BDTX: Strong clinical and financial performance, with silevertinib advancing and cash runway to 2028 - TradingView
Silevertinib data and Servier pact shape Black Diamond (NASDAQ: BDTX) - Stock Titan
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
[8-K] Black Diamond Therapeutics, Inc. Reports Material Event | BDTX SEC FilingForm 8-K - Stock Titan
1.33%
1.07%
大文字化:
|
ボリューム (24 時間):